Literature DB >> 17159245

Assessment of malignancy in adrenal cortical tumors.

Anne Marie McNicol1.   

Abstract

The roles of the pathologist in assessing adrenal cortical tumors are, first, to differentiate adenoma from carcinoma, and, second, to assess prognosis when the diagnosis of malignancy is made. How easy is it to achieve these goals with standard histology and immunohistochemistry, and to what extent can molecular analysis help?

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17159245     DOI： 10.1385/ep:17:2:131

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN： 1046-3976            Impact factor:   3.943


  35 in total

1.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy.

Authors:  Florence de Fraipont; Michelle El Atifi; Nadia Cherradi; Gwennaelle Le Moigne; Geneviève Defaye; Rémi Houlgatte; Jérôme Bertherat; Xavier Bertagna; Pierre-François Plouin; Eric Baudin; François Berger; Christine Gicquel; Olivier Chabre; Jean-Jacques Feige
Journal:  J Clin Endocrinol Metab       Date:  2004-12-21       Impact factor: 5.958

2.  Cellular DNA profiles of benign and malignant adrenocortical tumors.

Authors:  E S Cibas; L J Medeiros; D S Weinberg; A B Gelb; L M Weiss
Journal:  Am J Surg Pathol       Date:  1990-10       Impact factor: 6.394

3.  Staging and grading in the survival of adrenal carcinomas.

Authors:  G C Zografos; D Driscoll; C Karakousis; U Rao; R Huben
Journal:  Eur J Surg Oncol       Date:  1994-08       Impact factor: 4.424

4.  Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors.

Authors:  L Barzon; M Chilosi; F Fallo; G Martignoni; L Montagna; G Palù; M Boscaro
Journal:  Eur J Endocrinol       Date:  2001-08       Impact factor: 6.664

5.  Discerning malignancy in adrenocortical tumors: are molecular markers useful?

Authors:  C Wachenfeld; F Beuschlein; O Zwermann; P Mora; M Fassnacht; B Allolio; M Reincke
Journal:  Eur J Endocrinol       Date:  2001-09       Impact factor: 6.664

6.  Telomerase activity in the differentiation of benign and malignant adrenal tumors.

Authors:  L Teng; O Tucker; C Malchoff; E D Vaughan; J Jacobson; T J Fahey
Journal:  Surgery       Date:  1998-12       Impact factor: 3.982

7.  Proliferation in Adrenocortical Tumors: Correlation with Clinical Outcome and p53 Status.

Authors:  Anne M. McNicol; Andrew L. Struthers; Claire E. Nolan; Jo Hermans; Harm R. Haak
Journal:  Endocr Pathol       Date:  1997       Impact factor: 3.943

8.  p53 mutations in sporadic adrenocortical tumors.

Authors:  H Ohgaki; P Kleihues; P U Heitz
Journal:  Int J Cancer       Date:  1993-05-28       Impact factor: 7.396

9.  Increasing genome instability in adrenocortical carcinoma progression with involvement of chromosomes 3, 9 and X at the adenoma stage.

Authors:  A J Russell; J Sibbald; H Haak; W N Keith; A M McNicol
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

10.  Nuclear DNA content and morphological characteristics in the prognosis of adrenocortical carcinoma.

Authors:  H R Haak; C J Cornelisse; J Hermans; L Cobben; G J Fleuren
Journal:  Br J Cancer       Date:  1993-07       Impact factor: 7.640
View more
  1 in total

Review 1.  [New aspects of tumor pathology of the adrenal glands].

Authors:  W Saeger
Journal:  Pathologe       Date:  2015-05       Impact factor: 1.011
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.